24
19
1
49
2
2
2c
1b
1d
18
2f
63
1d
2 29
1d
25
Shivani Kapur, MD
88
63
Assistant Professor of Clinical Medicine (Hematology-Oncology)
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
53
4
3
3
3
2
4
b
1f
53
Perelman Center for Advanced Medicine
22 12th Floor, South Pavilion
33 3400 Civic Blvd.
Philadelphia, PA 19104
26
22 12th Floor, South Pavilion
33 3400 Civic Blvd.
Philadelphia, PA 19104
35
a9
12
13
Education:
21 7 MD 16 (Medicine ) c
33 B.J. Govet Medical College, 2015.
c
3
3
3
3
8d
Permanent link21 7 MD 16 (Medicine ) c
33 B.J. Govet Medical College, 2015.
c
2 29
21
1e
1d
24
2b
29
27
23
207 Cohen, A., Susanibar-Adaniya, S., Garfall, A., Vogl, D., Kapur, S., Waxman, A., Zubka, D., Hwang, W.T., Diaczynsky, C., Noll, J. and Ho, M.: Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy: Preliminary Safety and Efficacy Data from the “STEM”(Sequential T Cell-Engagement for Myeloma) Trial. The American Society of Hematology Annual Meeting, Orlando, FL. Elsevier, 25: 366, Dec 2025 Notes: "Poster Presentation"
19c Paruzzo, L., Luo, T., Ho, M., Patel, H., Stella, F., Vogl, D., Kapur, S., Waxman, A., Porazzi, P., Carturan, A. and Pucillo, M.: Consolidative Use of BCMA CAR-T Therapy in Relapsed/Refractory Myeloma—A Retrospective Evaluation. American Society of Hematology Annual Meeting, Orlando, FL. 25: 92-93. Dec 2025 Notes: "Poster Presentation"
18e Paruzzo, L., Eshaghi, K., Ghilardi, G., Doucette, A., Ho, M., Carturan, A., Vogl, D.T., Waxman, A.J., Kapur, S., Fardella, E. and Pucillo, M.: Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma. Blood Immunology & Cellular Therapy. Elsevier, 1(2): 100007, Sep 2025.
168 Yu, K., Ho, M., Paruzzo, L., Patel, H., Ruella, M., Kapur, S., Waxman, A., Vogl, D., Cohen, A., Stadtmauer, E. and Garfall, A.: Clinical Outcomes after Teclistamab Failure in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. Elsevier, 25: S64-S65, Sep 2025.
19d Matthew Ho, Luca Paruzzo, Julia Noll, Federico Stella, Sonia Ndeupen, Pooja Devi, Adam Waxman, Shivani Kapur, Fang Chen, Rong Xu, Andrew Huff, Peter Michener, Vanessa Gonzalez, Dan Vogl, David Porter, Aoife Roche, John Everett, Frederic Bushman, Katherine Nathanson, Edward Stadtmauer, Sandra Susanibar-Adaniya, Alfred Garfall, Marco Ruella, Joseph Fraietta, Adam Cohen 91 : CD4+ T-Cells Mediate Immune-Related Adverse Events (CirAE) Following BCMA CAR-T Therapy. Clinical Lymphoma Myeloma and Leukemia. 35 Elsevier, 25(3): p.S3. Sep 2025.
1f4 Luo, T., Paruzzo, L., Susanibar Adaniya, S.P., Garfall, A.L., Ho, M., Kapur, S., Ruella, M., Stadtmauer, E.A., Stella, F., Vogl, D.T. and Waxman, A.J.: Disease response at apheresis and association with long-term outcomes following CAR-T cells for relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology/American Society of Oncology Annual Meeting, Chicago, IL. 43: 7518, Jun 2025 Notes: "Poser Presentation"
191 Vogl, D.T., Nefedova, Y., Wileyto, E.P., Whittington, S., Diaczynsky, C., Nguyen, C.T., Strakovsky, I., Bondesson, E., Tuvesson, H., Vahtola, E. and Cohen, A.D.: Clinical Activity of Novel Targeting of S100A9 with Tasquinimod for Relapsed and Refractory Multiple Myeloma (RRMM). American Society of Clinical Oncology Annual Meeting, Chicago, IL. 46 43: 7555, Jun 2025 Notes: "Poster Presentation"
176 Ho, M., Paruzzo, L., Minehart, J., Voruganti, T., Devi, P., Vogl, D.T., Cohen, A.D., Garfall, A.L., Waxman, A.J., Kapur, S. and Stadtmauer, E.A.: Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma. Haematologica. Ferrata-Storti Foundation, 110(6): 1436-1442, Feb 2025.
183 Elghawy, O., Deshpande, S., Sussman, J., Garfall, A., Cohen, A., Kapur, S., Susanibar-Adaniya, S., Vogl, D., Waxman, A. and Stadtmauer, E.: Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. Nature: Bone Marrow Transplantation. Nature Publishing Group UK 2c 60(1): 64-68, Jan 2025.
2c
7
1d
1f
Selected Publications
1c8 Patel, H., Hubbeling, H., Yu, K., Carpenter, M., LaRiviere, M., Cohen, A., Kapur, S., Vogl, D., Waxman, A., Stadtmauer, E. and Garfall, A.: Outcomes of Radiation Therapy Integrated with T-cell Engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma. American Society of Hematology Annual Meeting, Orlando, FL. Elsevier, 25: 99, Dec 2025 Notes: "Poster Presentation"207 Cohen, A., Susanibar-Adaniya, S., Garfall, A., Vogl, D., Kapur, S., Waxman, A., Zubka, D., Hwang, W.T., Diaczynsky, C., Noll, J. and Ho, M.: Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy: Preliminary Safety and Efficacy Data from the “STEM”(Sequential T Cell-Engagement for Myeloma) Trial. The American Society of Hematology Annual Meeting, Orlando, FL. Elsevier, 25: 366, Dec 2025 Notes: "Poster Presentation"
19c Paruzzo, L., Luo, T., Ho, M., Patel, H., Stella, F., Vogl, D., Kapur, S., Waxman, A., Porazzi, P., Carturan, A. and Pucillo, M.: Consolidative Use of BCMA CAR-T Therapy in Relapsed/Refractory Myeloma—A Retrospective Evaluation. American Society of Hematology Annual Meeting, Orlando, FL. 25: 92-93. Dec 2025 Notes: "Poster Presentation"
18e Paruzzo, L., Eshaghi, K., Ghilardi, G., Doucette, A., Ho, M., Carturan, A., Vogl, D.T., Waxman, A.J., Kapur, S., Fardella, E. and Pucillo, M.: Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma. Blood Immunology & Cellular Therapy. Elsevier, 1(2): 100007, Sep 2025.
168 Yu, K., Ho, M., Paruzzo, L., Patel, H., Ruella, M., Kapur, S., Waxman, A., Vogl, D., Cohen, A., Stadtmauer, E. and Garfall, A.: Clinical Outcomes after Teclistamab Failure in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. Elsevier, 25: S64-S65, Sep 2025.
19d Matthew Ho, Luca Paruzzo, Julia Noll, Federico Stella, Sonia Ndeupen, Pooja Devi, Adam Waxman, Shivani Kapur, Fang Chen, Rong Xu, Andrew Huff, Peter Michener, Vanessa Gonzalez, Dan Vogl, David Porter, Aoife Roche, John Everett, Frederic Bushman, Katherine Nathanson, Edward Stadtmauer, Sandra Susanibar-Adaniya, Alfred Garfall, Marco Ruella, Joseph Fraietta, Adam Cohen 91 : CD4+ T-Cells Mediate Immune-Related Adverse Events (CirAE) Following BCMA CAR-T Therapy. Clinical Lymphoma Myeloma and Leukemia. 35 Elsevier, 25(3): p.S3. Sep 2025.
1f4 Luo, T., Paruzzo, L., Susanibar Adaniya, S.P., Garfall, A.L., Ho, M., Kapur, S., Ruella, M., Stadtmauer, E.A., Stella, F., Vogl, D.T. and Waxman, A.J.: Disease response at apheresis and association with long-term outcomes following CAR-T cells for relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology/American Society of Oncology Annual Meeting, Chicago, IL. 43: 7518, Jun 2025 Notes: "Poser Presentation"
191 Vogl, D.T., Nefedova, Y., Wileyto, E.P., Whittington, S., Diaczynsky, C., Nguyen, C.T., Strakovsky, I., Bondesson, E., Tuvesson, H., Vahtola, E. and Cohen, A.D.: Clinical Activity of Novel Targeting of S100A9 with Tasquinimod for Relapsed and Refractory Multiple Myeloma (RRMM). American Society of Clinical Oncology Annual Meeting, Chicago, IL. 46 43: 7555, Jun 2025 Notes: "Poster Presentation"
176 Ho, M., Paruzzo, L., Minehart, J., Voruganti, T., Devi, P., Vogl, D.T., Cohen, A.D., Garfall, A.L., Waxman, A.J., Kapur, S. and Stadtmauer, E.A.: Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma. Haematologica. Ferrata-Storti Foundation, 110(6): 1436-1442, Feb 2025.
183 Elghawy, O., Deshpande, S., Sussman, J., Garfall, A., Cohen, A., Kapur, S., Susanibar-Adaniya, S., Vogl, D., Waxman, A. and Stadtmauer, E.: Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. Nature: Bone Marrow Transplantation. Nature Publishing Group UK 2c 60(1): 64-68, Jan 2025.
2c
44
23
Back to Top
1b
1d
18